Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Risk Management Plans to Be Required from April 2013 to Strengthen Post-Marketing Safety Measures
April 18, 2012
-
BUSINESS Eli Lilly Japan Pinning New Hopes on Solanezumab; Will the Introduction of Medicoeconomic Assessments Help?
April 18, 2012
-
BUSINESS Generic Names Used in 25% of Prescriptions Issued by GPs: Nihon Chouzai
April 17, 2012
-
BUSINESS Over 60% of Drug Makers Increased Hiring of New Graduates in 2012: Jiho Survey
April 16, 2012
-
BUSINESS Takeda to Acquire URL Pharma, Boost US Business Base Through Field of Gout
April 13, 2012
-
REGULATORY CSIMC Expert Subcommittee to Begin Discussion on Long-Listed Drugs in June, Also Deliberate on Targets for Generic Products
April 13, 2012
-
BUSINESS Pfizer Focuses on Personalized Medicine for Oncology Area with Xalkori
April 12, 2012
-
BUSINESS Sanofi Pasteur Targets Double Sales in Japan, Enters 4 Products Including IPV
April 11, 2012
-
REGULATORY PMDA to Establish Forum for Discussions Between Reviewers and Outside Researchers to Upgrade Its Ability to Review Cutting-Edge Drugs
April 10, 2012
-
BUSINESS Generics Made in India to Storm Japanese Market with Overwhelming Price Advantage
April 10, 2012
-
ACADEMIA Generic Name Prescriptions Rapidly Rise on New Premium, Tokyo Pharmaceutical Association Issues Warning
April 9, 2012
-
BUSINESS MTPC Complements Alliance with BIKEN to Establish Its Own Vaccine Development Infrastructure
April 6, 2012
-
REGULATORY MHLW to Issue 80 Requests for Development of Unapproved Drugs/Indications This Week
April 5, 2012
-
BUSINESS Mochida Aims for Sales of Over 100 Billion Yen in FY2014: New Midterm Management Plan
April 4, 2012
-
REGULATORY PMDA Strengthens Consultation System to Support Biomarker Development
April 3, 2012
-
REGULATORY DPJ’s PAL Subcommittee to Hold Off Final Recommendation on PAL Amendment Until Late April
April 2, 2012
-
REGULATORY MHLW Proposes Pricing of Long-Listed Products to Be Concluded in FY2013: CSIMC Meeting
March 30, 2012
-
BUSINESS Fujifilm, Kyowa Hakko Kirin Establish JV to Develop Biosimilars
March 29, 2012
-
BUSINESS Astellas to Place Greater Importance on China Business: Executive Katayanagi
March 28, 2012
-
REGULATORY Use of Medicoeconomic Assessment in Drug Pricing “Unrealistic”: DG for Policy Planning and Evaluation Katori
March 28, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…